Technology

Impulse Dynamics' core technology involves the control of individual cell activity during a time period when the cell is already electrically active. The electrical signals applied from an electrode produce an immediate and powerful modulating effect on the normal function of the affected cells.

This therapy can be delivered with a high degree of specificity; delivering therapy directly to a specific location within the target organ ensures maximal response and enables control of the dose-response relationship. The therapy can be turned on and off at will.

Impulse Dynamics has achieved significant progress in the field of cardiology with the advancement of Cardiac Contractility Modulation (CCM). CCM is a unique method for treating the failing heart; nonstimulatory impulses are delivered during the absolute refractory period (ARP) and are intended to enhance contractility and overall cardiac performance.

The most common forms of heart failure are treated with drugs, pacing devices and other currently available methods. Available pharmacological therapies are primarily focused on restoring fluid balance (diuretics) or counteracting secondary neurohormonal derangements, which contribute to the remodeling process (ACE inhibitors, beta blockers and aldosterone inhibitors). Biventricular pacing, for patients with less severe heart failure, has recently been introduced to the market but is applicable to a small fraction of the CHF population. As the severity of the disease increases, more aggressive alternative therapies come into play, such as the use of positive inotropic agents (beta-adrenergic agonists, phosphodiesterase inhibitors), heart transplantation and left ventricular assist devices.